Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities    
Net loss $ (20,353) $ (94,785)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 3,824 2,728
Amortization 253 419
Gain on bargain purchase (22,155)  
Share-based compensation expense 5,513 10,631
Unrealized foreign exchange losses/(gains) 377 (108)
(Accretion)/amortization on available-for-sale debt securities (633) 1,636
Other 663 585
Changes in operating assets and liabilities:    
Decrease/(increase) in receivables and other operating assets 1,971 (22,898)
(Decrease)/increase in payables and other current liabilities (8,801) 12,898
Decrease in deferred revenue (41,704) (6,758)
Net cash used in operating activities (81,045) (95,652)
Cash flows from investing activities    
Acquisition of property, plant and equipment (3,565) (16,074)
Acquisition of intangible assets (199)  
Acquired upon acquisition of TCR2 Therapeutics Inc. 45,264  
Maturity or redemption of marketable securities 76,119 97,605
Investment in marketable securities (67,121) (42,197)
Other 537  
Net cash provided by investing activities 51,035 39,334
Cash flows from financing activities    
Proceeds from issuance of common stock from offerings, net of commissions and issuance costs 188 9,976
Proceeds from exercise of stock options 22 36
Net cash provided by financing activities 210 10,012
Effect of currency exchange rate changes on cash, cash equivalents and restricted cash 398 (5,836)
Net decrease in cash, cash equivalents and restricted cash (29,402) (52,142)
Cash, cash equivalents and restricted cash at start of period 109,602 151,666
Cash, cash equivalents and restricted cash at end of period $ 80,200 $ 99,524